The units sold under the Offering were issued and sold pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 Prospectus Exemptions (the "Listed Issuer Financing Exemption"). A copy of the offering document under the Listed Issuer Financing Exemption dated May 30, 2024 is available under the Company's profile at www.sedarplus.ca and on the Company's website at www.cruzbatterymetals.com. All units issued pursuant to the Listed Issuer Financing Exemption are not subject ...

. . June 10, 2024 7:00 AM EDT | Source: BMEX Gold Inc The Offering will consist of the sale of a minimum of 2,000,000 non-flow-through units ("NFT Units") at $0.15 per NFT Unit for gross non-flow-through proceeds of $300,000, and will also include a maximum of up to 6,666,667 flow-through units ("FT Unit") at $0.15 per FT Unit for gross flow-through proceeds of up to $1,000,000. Each FT Unit and each NFT Unit consists of one common share (a "Common Share") of the Company and one full common share purchase w ...

NEW ORLEANS, June 05, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwise acquired the Company's shares between May 8, 2019 and April 10, 2024, inclusive (the "Class Period"). Long term holders of GL are also encouraged to contact the firm. This action is pending in ...

Company Overview - aTyr Pharma, Inc. is a clinical stage biotechnology company focused on discovering and developing first-in-class medicines from its proprietary tRNA synthetase platform [1][2] - The company is advancing its lead therapeutic candidate, efzofitimod, through a pivotal Phase 3 study in pulmonary sarcoidosis, with potential commercialization on the horizon [1][2] Ticker Symbol Change - The company will change its ticker symbol from "LIFE" to "ATYR," effective June 5, 2024, to better reflect its corporate identity and enhance visibility [1] - Existing stockholders do not need to take any action regarding the ticker symbol change, and the common stock will continue to be listed on the Nasdaq Capital Market [1] Therapeutic Focus - aTyr's lead candidate, efzofitimod, is a first-in-class biologic immunomodulator in clinical development for treating interstitial lung disease, which includes immune-mediated disorders causing lung inflammation and progressive fibrosis [2]

Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - Cruz Battery Metals Corp. (CSE: CRUZ) (OTC Pink: BKTPF) (FSE: A3CWU7) ("Cruz" or the "Company") has arranged a non-brokered listed issuer financing exemption (LIFE) private placement of up to 6,250,000 units at a price of $0.036 per unit. Each unit will comprise of one common share of the Company and one share purchase warrant to purchase one common share of the Company at a price of $0.05 for a period of 60 months from the Closing Date. The Off ...

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. tRNA synthetases are ancient, essential proteins that have evolved novel domains that regulate diverse pathways extracellularly in humans. aTyr's discovery platform is focused on unlocking hidden therapeutic intervention points by uncovering signaling pathways driven by its proprietary library of domains derived from all 20 tRNA synthetase ...

On this news, the price of Globe Life's shares fell by $55.76 per share, or 53%, from a closing price of $104.93 per share on April 10, 2024, to a closing price of $49.17 per share on April 11, 2024. NEW ORLEANS, May 17, 2024 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 1, 2024 to file lead plaintiff applications in a securities class action lawsuit against Globe Life Inc. f/k/a Torchmark Corporation (NYSE: GL), if they purchased or otherwi ...

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units (each, a "Unit"), at a price of $0.04 per Unit; (the "Offering"). The Offering is being led by EMD Financial Inc. Each Unit will be comprised of one common share ("Common Share") in the capital of ...

Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE) (aTyr or the "Company"), a clinical stage biotechnology company engaged in the discovery and development of first-in- class medicines from its proprietary tRNA synthetase platform, today announced that an independent data and safety monitoring board (DSMB) r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37378 ATYR PHARMA, INC. (Exact name of registrant as specified in its charter) Delaware 20-3435077 (State or other jurisdiction ...